USP Responding To Congress' Questions On Medicare Formulary Guidelines
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. Pharmacopeia has provided information to two congressional committees as it moves toward finalizing its model formulary guidelines for the Medicare drug benefit. USP emphasizes that no decision on the final structure of the guidelines has been made; final recommendations to CMS are expected by year-end.
You may also be interested in...
PCMA Launches Ad Campaign On Medicare Formulary Design
Print ad asks "Guess who's coming to dinner?" and features a sumo wrestler representing "the big drug companies." Inside-the-Beltway advertising campaign is designed to ensure that Medicare Rx formulary design permits current market practices, the PBM association says.
PCMA Launches Ad Campaign On Medicare Formulary Design
Print ad asks "Guess who's coming to dinner?" and features a sumo wrestler representing "the big drug companies." Inside-the-Beltway advertising campaign is designed to ensure that Medicare Rx formulary design permits current market practices, the PBM association says.
Lawmakers Begin Lobbying CMS Over Medicare Drug Formularies
Sen. Smith (R-Ore.) expresses concern about classification of antidepressants in U.S. Pharmacopeia's Medicare formulary guidelines during Senate Finance Committee hearing.